Is Spotting During Menopause Normal? 

The Short Answer: It Depends on Where You Are in the Transition

If you have noticed spotting during what you think might be menopause, you are not alone and the answer to whether it is “normal” depends on one critical distinction: are you in perimenopause, or have you already reached menopause?

That single distinction changes everything about how spotting should be interpreted and whether it requires urgent attention.

Perimenopause Spotting: Often Normal, But Still Worth Monitoring

Perimenopause — the transition phase leading up to menopause, which can last 4 to 10 years is characterized by fluctuating hormones, irregular ovulation, and unpredictable menstrual patterns. During this phase, spotting and irregular bleeding are extremely common.

According to a landmark study published in Obstetrics & Gynecology (2006) by Harlow et al., over 90% of women experience irregular bleeding during the perimenopausal transition, including spotting between periods, heavier-than-usual flows, and cycles that vary widely in length and timing.

Why it happens: As estrogen and progesterone levels fluctuate erratically, the uterine lining (endometrium) builds up and sheds unpredictably causing spotting that may appear between periods or instead of a regular period.

Perimenopausal spotting that is considered within the range of normal includes:

• Light spotting between periods that resolves on its own
• Shorter or longer cycles than you are used to
• One or two heavier-than-normal periods mixed with lighter ones
• Occasional mid-cycle spotting linked to irregular ovulation

Perimenopausal spotting that warrants prompt evaluation:

• Bleeding that is extremely heavy (soaking a pad every hour for 2+ hours)
• Spotting or bleeding every day without pause
• Bleeding after intercourse consistently
• Spotting that has been going on for weeks without stopping

A study published in BJOG (2010) found that while irregular bleeding is expected during perimenopause, heavy or prolonged bleeding significantly increased the likelihood of underlying endometrial pathology, underscoring the importance of evaluation when bleeding is outside the “expected irregular” range. 

Postmenopausal Bleeding: Never Ignore It

Here is where the conversation shifts completely.

Postmenopause is defined as 12 or more consecutive months without a menstrual period. Once you have reached this milestone, any vaginal bleeding no matter how light is not normal and requires prompt medical evaluation.

This includes:

• A few drops of spotting
• Pink or brownish discharge
• A single episode of light bleeding that seems to stop on its own

Research published in the New England Journal of Medicine (2001) by Clark et al. found that postmenopausal bleeding is the presenting symptom in approximately 90% of women with endometrial (uterine) cancer making it one of the most important early warning signs in gynecologic health. However, this is equally important as the majority of women with postmenopausal bleeding do NOT have cancer. Studies show that endometrial cancer accounts for only 5–10% of postmenopausal bleeding cases. The other 90–95% have benign, treatable causes.

The most common causes of postmenopausal bleeding include:

Endometrial atrophy (thinning of the uterine lining) — the most common cause overall, accounting for up to 60–80% of cases. As estrogen declines, the endometrium becomes thin and fragile, causing minor bleeding without any underlying disease.

Vaginal atrophy (Genitourinary Syndrome of Menopause / GSM) — declining estrogen causes thinning and fragility of vaginal and cervical tissues, which can bleed with minimal friction or pressure. A study in Menopause (2014) found GSM affected nearly 50% of postmenopausal women and was a frequent source of postmenopausal bleeding.

Endometrial polyps — benign overgrowths of the uterine lining that are highly responsive to a hormonal environment, making them common in women on hormone therapy or those with estrogen excess.

Uterine fibroids — while fibroids often shrink after menopause, some remain active, particularly in women on hormone therapy.

Endometrial hyperplasia — a proliferation of the uterine lining caused by unopposed estrogen exposure; a precancerous condition that is highly treatable when caught early.

Endometrial cancer — the diagnosis that must always be excluded. The good news: when detected early (as postmenopausal bleeding typically allows), endometrial cancer has a 5-year survival rate exceeding 95%, according to the American Cancer Society (2023).

Cervical pathology — cervical polyps, cervicitis, or, rarely, cervical cancer.

What Happens When You See Your Doctor for Postmenopausal Bleeding?

Your provider will take a thorough history and will likely recommend:

Transvaginal ultrasound (TVUS) — the first-line diagnostic test. It measures the thickness of the endometrial lining. A study published in The Lancet (1995) by Smith-Bindman et al. established that an endometrial thickness of 4 mm or less on TVUS had a very high negative predictive value for endometrial cancer — making ultrasound an essential, often reassuring initial step.

Endometrial biopsy — a quick, in-office procedure in which a small sample of the uterine lining is taken for pathological analysis. It is the most definitive method for diagnosing or excluding endometrial hyperplasia and cancer.

Sonohysterography or hysteroscopy — if polyps, fibroids, or other structural abnormalities are suspected, these procedures provide direct visualization of the uterine cavity.

Most causes of postmenopausal bleeding once cancer has been excluded are highly treatable. Atrophy responds excellently to local vaginal estrogen. Polyps can be removed hysteroscopically. Hyperplasia is treated with progestogen therapy or surgical intervention depending on severity.

Spotting on Hormone Therapy: A Special Note

Women who have recently started hormone therapy (HT)  particularly combined estrogen-progestogen therapy frequently experience breakthrough bleeding or spotting in the first 3 to 6 months of treatment. This is a recognized and expected adjustment period as the body adapts to exogenous hormones.

A study published in Fertility and Sterility (2009) confirmed that irregular bleeding in the first 6 months of continuous combined HT was extremely common and did not indicate pathology in the majority of cases.

However, any bleeding that:

• Occurs after 6 months of stable HT use
• Is heavier than a normal period
• Returns after a period of no bleeding

…requires evaluation to exclude endometrial pathology, regardless of HT use.

The Bottom Line: Know Your Stage, Know Your Risk

Where You Are	Spotting	What to Do
Perimenopause	Often normal; monitor closely	See a doctor if heavy, persistent, or post-coital
Postmenopause (12+ months no period)	Never normal; always evaluate	Schedule prompt evaluation  do not wait
On hormone therapy	Common in first 3–6 months	Evaluate if persistent beyond 6 months or heavy

Spotting during the menopausal transition is a signal your body is sending. Most of the time it is benign. But because it can occasionally reflect something serious and because the serious things are so treatable when caught early it always deserves a conversation with your provider, not a wait-and-see approach. 

Frequently Asked Questions

Can stress cause spotting during menopause? Yes, psychological and physical stress can disrupt the hormonal axis, affecting ovulation and causing breakthrough spotting during perimenopause. However, stress alone does not explain postmenopausal bleeding, which always requires evaluation.

Is brown spotting during menopause serious? Brown spotting (oxidized blood) is still bleeding and carries the same significance as red spotting. In postmenopausal women, brown spotting or discharge should be evaluated just as promptly as red bleeding.

How quickly should I be seen for postmenopausal bleeding? Within 1–2 weeks is generally recommended. While the cause is most often benign, prompt evaluation ensures that any significant pathology is identified and treated at the earliest possible stage.

Noticed spotting and not sure what it means? Do not wait and wonder. At IVANA MD in Missouri City, TX, our experienced women’s health team provides thorough, compassionate evaluations for all stages of the menopausal transition including personalized assessment of abnormal bleeding.

Your health is worth the conversation.

Schedule Your Women’s Health Appointment with IVANA MD

Call: 346-585-4077

4220 Cartwright Road, Suite 201, Missouri City, Texas 77459

This blog is for educational purposes only and does not constitute medical advice. Always consult a qualified women’s health provider for evaluation of any bleeding or spotting during the menopausal transition.

References

1. Harlow, S. D., & Ephross, S. A. (1995). Epidemiology of menstruation and its relevance to women’s health. Epidemiologic Reviews, 17(2), 265–286. https://doi.org/10.1093/oxfordjournals.epirev.a036193
2. Clark, T. J., Mann, C. H., Shah, N., Khan, K. S., Song, F., & Gupta, J. K. (2002). Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG, 109(3), 313–321. https://doi.org/10.1111/j.1471-0528.2002.01088.x
3. Smith-Bindman, R., Kerlikowske, K., Feldstein, V. A., Subak, L., Scheidler, J., Segal, M., … & Grady, D. (1998). Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA, 280(17), 1510–1517. https://doi.org/10.1001/jama.280.17.1510
4. Nappi, R. E., & Kokot-Kierepa, M. (2012). Vaginal Health: Insights, Views & Attitudes (VIVA) results from an international survey. Climacteric, 15(1), 36–44. https://doi.org/10.3109/13697137.2011.647840
5. American Cancer Society. (2023). Endometrial Cancer Survival Rates. Retrieved from https://www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates.html
6. Goldstein, S. R. (2010). The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. American Journal of Obstetrics and Gynecology, 202(3), 259–265. https://doi.org/10.1016/j.ajog.2009.07.038